News
- Author:
- Mary Ellen Schneider
Publish date: October 5, 2018
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.
News
- Author:
- Mary Ellen Schneider
Publish date: October 5, 2018
The small study showed high response and no significant safety concerns.
Article
- Author:
- Mary Ellen Schneider
Publish date: October 2, 2018
Takeda Pharmaceuticals and Seattle Genetics announced phase 3 trial results in frontline treatment of peripheral T-cell lyphoma (PTCL).
News
- Author:
- Mary Ellen Schneider
Publish date: September 14, 2018
At least four new mantle cell lymphoma trials were registered in Clinicaltrials.gov in August 2018.
News
- Author:
- Mary Ellen Schneider
Publish date: August 29, 2018
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
- Author:
- Mary Ellen Schneider
Publish date: August 22, 2018
Dr. Daniel Bauer of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, was recognized for his research on sickle cell disease and bet...
News
- Author:
- Mary Ellen Schneider
Publish date: August 2, 2018
The promising results suggest bone marrow involvement could be assessed without a biopsy.
News
- Author:
- Mary Ellen Schneider
Publish date: July 20, 2018
The study looked at ibrutinib safety for CLL/SLL and MCL across four studies.
News
- Author:
- Mary Ellen Schneider
Publish date: July 18, 2018
The agency issued three disease-specific gene therapy guidances, including for retinal disorders and rare diseases.
News
- Author:
- Mary Ellen Schneider
Publish date: July 18, 2018
Fidanacogene elaparvovec is an investigational gene therapy aimed at allowing hemophilia B patients to live free of routine infusions.
News
- Author:
- Mary Ellen Schneider
Publish date: July 17, 2018
Researchers identified factors that predict which pediatric ALL patients were likely to have a longer hospital stay after induction chemotherapy.
News
- Author:
- Mary Ellen Schneider
Publish date: July 13, 2018
The British Society for Haematology has issued updated guidance that incorporates new drugs and transplant data.<...
News
- Author:
- Mary Ellen Schneider
Publish date: July 13, 2018
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
News
- Author:
- Mary Ellen Schneider
Publish date: June 29, 2018
The therapies must be approved by the European Commission before they can be marketed to patients.
News
- Author:
- Mary Ellen Schneider
Publish date: June 29, 2018
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
